Ellen Kurek

News
Costs Associated With the Use of a Health System Specialty Pharmacy Health Care for Medicare Advantage Beneficiaries
05/11/2022
Use of a health system specialty pharmacy may be associated with a lower health care cost, according to a retrospective cohort study that examined Medicare Advantage beneficiaries' medical and pharmacy claims from 2018 and 2019.
Use of a health system specialty pharmacy may be associated with a lower health care cost, according to a retrospective cohort study that examined Medicare Advantage beneficiaries' medical and pharmacy claims from 2018 and 2019.
Use of a health system specialty...
05/11/2022
Journal of Clinical Pathways
News
Defining the Notion of Value in Oncology Treatment
07/07/2022
A recent article discusses oncology-specific considerations when assessing elements of value, offering some background on the nature and development of quality-adjusted life-years as a part of cost-effectiveness analyses and some of their key...
A recent article discusses oncology-specific considerations when assessing elements of value, offering some background on the nature and development of quality-adjusted life-years as a part of cost-effectiveness analyses and some of their key...
A recent article discusses...
07/07/2022
Journal of Clinical Pathways
News
Assessing Risk Factors for Progression Among Patients With Advanced Ovarian Cancer After Response to First-line Platinum-Based Chemotherapy
05/31/2022
Multiple factors were associated with shorter time to next treatment or overall survival in a recent retrospective real-world analysis on patients with ovarian cancer.
Multiple factors were associated with shorter time to next treatment or overall survival in a recent retrospective real-world analysis on patients with ovarian cancer.
Multiple factors were associated...
05/31/2022
Journal of Clinical Pathways
News
Survey Explores Prescriber Perceptions and Preferences Regarding First Line Therapy for MCL
07/27/2022
A survey evaluated first-line therapy preferences for treatment-naïve patients with MCL in routine practice and perceptions surrounding benefits and risks of the lenalidomide plus rituximab plus venetoclax triplet regimen.
A survey evaluated first-line therapy preferences for treatment-naïve patients with MCL in routine practice and perceptions surrounding benefits and risks of the lenalidomide plus rituximab plus venetoclax triplet regimen.
A survey evaluated first-line...
07/27/2022
Journal of Clinical Pathways
News
Time to Discontinuation of First-Line Venetoclax Plus Obinutuzumab Among Patients With CLL or SLL
04/08/2022
Patients with CLL or SLL who discontinued venetoclax as first-line therapy were older and had a greater disease burden and risk of tumor lysis syndrome when compared with those patients who completed at least 12 cycles of treatment, according...
Patients with CLL or SLL who discontinued venetoclax as first-line therapy were older and had a greater disease burden and risk of tumor lysis syndrome when compared with those patients who completed at least 12 cycles of treatment, according...
Patients with CLL or SLL who...
04/08/2022
Journal of Clinical Pathways
News
Biosimilar vs Referent Trastuzumab for the Neoadjuvant Treatment of ERBB2–Positive Breast Cancer
04/14/2022
Biosimilar HD201 demonstrates equal efficacy to referent trastuzumab in total pathological complete response and safety in ERBB2–positive breast cancer, according to results from the TROIKA trial.
Biosimilar HD201 demonstrates equal efficacy to referent trastuzumab in total pathological complete response and safety in ERBB2–positive breast cancer, according to results from the TROIKA trial.
Biosimilar HD201 demonstrates...
04/14/2022
Journal of Clinical Pathways
News
Cost-Effectiveness of Tumor Genomic Profiling to Among Patients With Metastatic Lung Adenocarcinoma
05/11/2022
When compared with no tumor profiling in patients with metastatic lung adenocarcinoma, tumor profiling may improve quality-adjusted survival but is not cost-effective.
When compared with no tumor profiling in patients with metastatic lung adenocarcinoma, tumor profiling may improve quality-adjusted survival but is not cost-effective.
When compared with no tumor...
05/11/2022
Journal of Clinical Pathways
News
Personalizing First-Line Treatments for Metastatic Renal Cell Carcinoma
07/12/2022
Researchers detail current first-line treatment options for the management of metastatic renal cell carcinoma and propose a framework for optimal treatment selection.
Researchers detail current first-line treatment options for the management of metastatic renal cell carcinoma and propose a framework for optimal treatment selection.
Researchers detail current...
07/12/2022
Journal of Clinical Pathways
News
Geriatric Assessment Instrument Utilization Among US Community Oncologists
05/31/2022
Findings from a recent study show that many oncologists have not incorporated geriatric assessment tools because of perceptions that standardized geriatric assessments are difficult to implement or do not add any value.
Findings from a recent study show that many oncologists have not incorporated geriatric assessment tools because of perceptions that standardized geriatric assessments are difficult to implement or do not add any value.
Findings from a recent study...
05/31/2022
Journal of Clinical Pathways
News
Outcomes of Patients With NSCLC Participating in Medicaid vs Commercial Insurance
06/12/2022
Findings from a recent study indicate that Medicaid patients with cancer may receive lower-quality care than those with commercial insurance.
Findings from a recent study indicate that Medicaid patients with cancer may receive lower-quality care than those with commercial insurance.
Findings from a recent study...
06/12/2022
Journal of Clinical Pathways

Upcoming Events

LLM Winter Symposium
February 7 ⁠–⁠ February 9
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
GD Solid Tumors
March 22 ⁠–⁠ March 23
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 4
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use